Athenex, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 280
- Market Cap
- -
- Website
- http://www.athenex.com
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05487651
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸OHSU - Knight Cancer Center, Portland, Oregon, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A PK Study of Oraxol in Breast Cancer Patients
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04993040
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Athenex, Inc.
- Registration Number
- NCT04878484
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04180384
- Locations
- 🇦🇺
Monash Medical Centre, Clayton, Australia
🇳🇿Auckland City Hospital, Auckland, New Zealand
🇳🇿Wellington Regional Hospital, Wellington, New Zealand
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04168957
- Locations
- 🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳Taipei Veterans Generla Hospital, Taipei, Taiwan, 11217, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
A Phase I Open-label Study for Subjects With Advanced Malignancies
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT04136834
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04035473
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇨🇳Lotung Poh-Ai Hospital, Ilan, Taiwan
🇳🇿Wellington Regional Hospital, Wellington, New Zealand
Evaluate Eribulin ORA in Subjects With Solid Tumors
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04013217
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03987685
- Locations
- 🇺🇸
HonorHealth Research Institute, Phoenix, Arizona, United States
🇬🇧Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle, United Kingdom
🇬🇧Cancer Research UK Clinical Trials Unit- The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03892018
- Locations
- 🇬🇧
The Beatson West of Scotland Cancer Care Centre, Glasgow, United Kingdom
🇬🇧The Northern Institute for Cancer Care, Newcastle Upon Tyne, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom